Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.

[1]  K. Poehling,et al.  Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  L. Grohskopf,et al.  Surveillance of Vaccination Coverage Among Adult Populations —United States, 2018 , 2021, Morbidity and mortality weekly report. Surveillance summaries.

[3]  Kenneth J. Smith,et al.  Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors. , 2021, American journal of preventive medicine.

[4]  B. Patterson,et al.  Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019 , 2021, Human vaccines & immunotherapeutics.

[5]  W. Lim,et al.  Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study , 2020, PLoS medicine.

[6]  Kenneth J. Smith,et al.  Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years , 2019, Journal of Community Health.

[7]  Kenneth J. Smith,et al.  Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S. , 2019, Journal of the National Medical Association.

[8]  Kenneth J. Smith,et al.  Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population. , 2019, Vaccine.

[9]  Eun Ji Kim,et al.  Racial and Ethnic Disparities in Diagnosis of Chronic Medical Conditions in the USA , 2018, Journal of General Internal Medicine.

[10]  M. Nowalk,et al.  Using the 4 Pillars to increase vaccination among high-risk adults: who benefits? , 2017, The American journal of managed care.

[11]  M. Bonten,et al.  The impact of community-acquired pneumonia on the health-related quality-of-life in elderly , 2017, BMC Infectious Diseases.

[12]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[13]  L. Kim,et al.  Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States , 2016, Journal of General Internal Medicine.

[14]  K. O'Brien,et al.  Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques , 2013, PloS one.

[15]  W. Schaffner,et al.  Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. , 2010, American journal of public health.

[16]  W. Anderson,et al.  State-Level Health Care Expenditures Associated With Disability , 2010, Public health reports.

[17]  C. Whitney,et al.  Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race , 2003, Annals of Internal Medicine.

[18]  R. Thompson,et al.  Safety of revaccination with pneumococcal polysaccharide vaccine. , 1999, JAMA.

[19]  D. Fryback,et al.  Toward consistency in cost-utility analyses: using national measures to create condition-specific values. , 1998, Medical care.